Abnova — Investor Presentation 2025

Jul 15, 2025

Abnova (Taiwan) Corp. (4133.TW) 2025 Investor Conference

2025/07/17

==> picture [680 x 110] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

Safe Harbor Notice

The following pages contain projections & estimates of financial information as well as market and product developments for future periods. These projections & estimates are based on information currently available which we believe to be reliable, but they involve risks & uncertainties. Our actual results of operations & financial condition may differ significantly from those contained in the projections & estimates. The projections & estimates should not be interpreted as legally binding commitments, but rather as flexible information subject to change occasionally.

2

Our Agenda

Abnova Company Profile Our History and Mission

Abnova Financial Results 2025 Q1 Financial Results, Revenue by Product

Abnova Product Updates The latest product development progress in 2025

3

Abnova Company Profile

4

Company Profile

==> picture [357 x 352] intentionally omitted <==

==> picture [362 x 75] intentionally omitted <==

==> picture [362 x 233] intentionally omitted <==

5

Website

==> picture [381 x 469] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

6

Product Map

==> picture [601 x 323] intentionally omitted <==

==> picture [601 x 69] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

7

E-Newsletter

==> picture [359 x 371] intentionally omitted <==

==> picture [378 x 350] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

8

Abnova Financial Results

9

Consolidated Income Statement

NTD Thousands Q1/25	NTD Thousands Q1/25	% Q4/24	% QoQ Q1/24	% YoY
Net Revenue	90,498	100% 88,044	100% 3% 85,003	100% 6%
Cost of Revenue	50,667	56% 49,651	56% 2% 44,052	52% 15%
Gross Profit	39,831	44% 38,393	44% 4% 40,951	48% -3%
Operating Expense	(33,237)	-37% (34,920)	-40% -5% (29,186)	-34% 14%
Operating Income	6,594	7% 3,473	4% 90% 11,765	14% -44%
Non-Operating Income and expense	8,866	10% 15,549	18% 43% 17,279	20% 49%
Income before Tax	15,460 13,605 0.22	17% 19,022 15% 13,490 0.22	22% -19% 29,044 15% 1% 26,704 0% 0.44	34% -47% 31% -49% -50%
Income after Tax
Basic EPS after Tax(NTD)

10

Revenue Breakdown by Product

==> picture [49 x 22] intentionally omitted <==

==> picture [409 x 263] intentionally omitted <==

==> picture [266 x 232] intentionally omitted <==

11

Abnova Product Updates

12

Abnova Product Updates

In Vivo Functional Grade Antibodies NanoAb[TM]

VLP and Nanodisc Membrane Proteins RNAutomation

13

In Vivo Functional Grade Antibodies

==> picture [773 x 308] intentionally omitted <==

==> picture [41 x 40] intentionally omitted <==

14

NanoAb[TM]

• Advantages

1. Small size for enhanced tissue penetration.

2. High affinity and remarkable stability.

3. Low immunogenicity and other properties render it ideal for diagnosis, treatment, and as versatile research tools.

4. Capable of large-scale production without the need for animals.

5. Abnova has developed 190+ nanobodies and continues to grow its catalog this year.

==> picture [367 x 323] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

15

NanoAb[TM]

 NanoAb[TM] conjugated FITC binding affinity assay

Mouse 4-1BB VHH-FITC Mouse CD83 VHH-FITC Human DR5 VHH-FITC Mouse TNFR2 VHH-FITC Clone: 8-2-21 Clone: 121-4-116 Clone: 156-1-100 Clone: 129-18-120 Mouse activated splenocyteMouse DC2.4 cell line Human Hela cell line Mouse activated splenocyteCD8 CD4

Mouse 4-1BB VHH-FITC Mouse CD83 VHH-FITC Clone: 8-2-21 Clone: 121-4-116

 NanoAb[TM] conjugated Aster 647 binding affinity assay

Human PD-L1 VHH-iFluor488 Clone: H140

==> picture [86 x 84] intentionally omitted <==

Human MDA-MB-231 cell line

 NanoAb[TM] conjugated iFluor 488 binding affinity assay

Human CD79a VHH-iFluor488 Human CD34 VHH-iFluor488 Clone: 2420 Clone: 5031

Mouse FOLR1 VHH-iFluor488 Mouse TIM-3 VHH-iFluor488 Clone: H135 Clone: 4017

==> picture [79 x 79] intentionally omitted <==

==> picture [80 x 79] intentionally omitted <==

==> picture [76 x 79] intentionally omitted <==

==> picture [80 x 76] intentionally omitted <==

==> picture [356 x 7] intentionally omitted <==

----- Start of picture text -----

Human activated PBMC Human KG-1 cell line Mouse 4T1 cell line Mouse activated splenocyte
----- End of picture text -----

 BiTE conjugated Dylight650 binding affinity assay

Human nPD-L1 X nCD3e BiTE-Dylight650

Human nPD-L1 X nCD3e BiTE-Dylight650

==> picture [87 x 86] intentionally omitted <==

Human CD8 T cells Human HT29 cell line

==> picture [41 x 41] intentionally omitted <==

16

VLP and Nanodisc Membrane Proteins

 Advantages

1. VLPs are made of viral capsid proteins that selfassemble into virus-like structures. They stably embed membrane proteins without genomes, making them safe for structural and functional display.

2. VLPs are easy to standardize and scale up, suitable for membrane protein applications such as antibody immunization, vaccine development, screening, and gene therapy.

3. Nanodiscs mimic cell membranes, preserving membrane protein structure and function with high stability and no need for detergents.

4. Nanodiscs make membrane proteins water soluble, enabling easier purification, analysis, and drug screening.

==> picture [336 x 82] intentionally omitted <==

==> picture [390 x 42] intentionally omitted <==

==> picture [91 x 81] intentionally omitted <==

==> picture [89 x 81] intentionally omitted <==

==> picture [87 x 78] intentionally omitted <==

==> picture [95 x 78] intentionally omitted <==

==> picture [78 x 82] intentionally omitted <==

==> picture [95 x 82] intentionally omitted <==

==> picture [87 x 73] intentionally omitted <==

==> picture [85 x 76] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

1717

RNAutomation

An Integrated Automation for Custom SAM, mRNA, circRNA Synthesis and Purification

==> picture [750 x 361] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

1818

==> picture [69 x 72] intentionally omitted <==

RNAutomation

mRNA Workflow

==> picture [575 x 361] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

1919

==> picture [69 x 72] intentionally omitted <==

RNAutomation

Application 1

• COVID-19 Omicron Variant mRNA Vaccine for Neutralizing Antibody Production

==> picture [576 x 332] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

2020

==> picture [69 x 72] intentionally omitted <==

RNAutomation

Application 2

• Anti-HER2 Biologic Synthesis by Intravenous mRNA Delivery

==> picture [622 x 318] intentionally omitted <==

==> picture [41 x 41] intentionally omitted <==

2121

RNAutomation Application 2

• Anti-HER2 Biologic Synthesis by Intravenous mRNA Delivery

2222

THANK YOU

  Innovate Transform Grow

==> picture [140 x 37] intentionally omitted <==

Innovate through Integrated Solutions www.abnova.com.tw

==> picture [147 x 137] intentionally omitted <==

==> picture [147 x 137] intentionally omitted <==

==> picture [146 x 69] intentionally omitted <==

==> picture [169 x 83] intentionally omitted <==

==> picture [146 x 69] intentionally omitted <==

==> picture [40 x 39] intentionally omitted <==